Understanding monoclonal antibody production cost: which stage of a custom monoclonal antibody project carries the money, what changes a custom antibody production cost quotation most, and the decisions taken at the start that decide the bill

Where the money goes, stage by stage

1. The immunogen, which is cheap to buy and expensive to get wrong. A peptide with carrier conjugation is inexpensive; a correctly folded recombinant protein or a membrane protein in a native conformation is a project in itself. A poor immunogen produces a campaign that finds nothing, which is the most expensive outcome available.
2. The discovery platform. Classical hybridoma work is well understood and takes months. Single B cell methods and display technologies are faster and cost more per campaign. The platform choice changes both the price and what kind of antibody you are likely to find.
3. The screen, which is where projects succeed or fail. Screening against the assay you will actually use costs more than screening on a generic binding assay, and it is the difference between a clone that works in your application and one that binds. Ask what the screening cascade is and insist your functional assay is in it.
4. The number of clones taken forward. Expanding, subcloning, freezing and characterising each candidate is per-clone work. A quotation for a campaign delivering one clone and one delivering five are different products, and the per-clone cost is the line to compare.
5. Sequencing and recombinant conversion. Delivering a hybridoma delivers a cell line that can drift or be lost; sequencing the variable regions and converting to a recombinant line makes the reagent permanent and reformattable. It costs more at the end and is almost always worth it for a reagent you will use for years.

What a quotation should be broken down into

Immunogen preparation, immunisation and monitoring, fusion or B cell isolation, primary screening with the number of wells, secondary screening with the assay named, clone expansion and freezing, characterisation, and optional sequencing. Ask for that breakdown and the comparison becomes possible.

Also ask what happens if the campaign finds nothing at the primary screen. A provider that repeats at its own cost and one that invoices and stops are very different propositions at the same headline price.

The costs after delivery that nobody quotes

Validating the clone in your own hands, producing and purifying working quantities, and conjugating it for your application are all yours. A delivered clone is the start of the reagent's life rather than the end of the project.

Budget a bank and a characterisation package. A clone with no frozen bank and no recorded specification is a liability the first time somebody asks what lot was used.

When a catalogue antibody is the better buy

If a well validated reagent against your target already exists, a custom campaign is a long way to reach the same place. Search the literature and the catalogues properly first, including the clone identities behind them, because several suppliers resell the same clone.

Custom work earns its cost for novel targets, for a specific epitope, for an application nobody else has validated, or where supply security over years matters more than the up-front figure.

Common questions

What drives monoclonal antibody production cost most?

The immunogen difficulty, the platform, the screening cascade and the number of clones delivered. Between two quotations for the same target, the screening cascade and the clone count usually explain most of the difference.

Why are two custom monoclonal antibody quotations so different?

Because they rarely cover the same scope. Check the immunogen work, whether your functional assay is in the screen, how many clones are characterised and delivered, and whether sequencing and recombinant conversion are included.

Should I pay for sequencing the clone?

For a reagent you intend to use for years, almost always. A sequenced and recombinantly expressed antibody cannot drift, cannot be lost with a freezer failure and can be reformatted into any isotype or fragment later.

Who owns the antibody?

Whatever the contract says. Ownership of the immunogen, the hybridoma, the sequence, the right to publish and the right to have it made elsewhere are separate terms and defaults differ between providers. Settle them before work starts.

Browse by service class

• Compare Gene synthesis on advertised prices